4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Aktierapport

Börsvärde: US$727.6m

4D Molecular Therapeutics Förvaltning

Förvaltning kriterier kontrolleras 3/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

David Kirn

Verkställande direktör

US$2.1m

Total ersättning

VD-lön i procent32.53%
Anställning som VD13yrs
Ägande av VD2.6%
Ledningens genomsnittliga anställningstid2yrs
Styrelsens genomsnittliga mandatperiod5.8yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jul 20

4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity

Summary 4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for Wet-AMD and DME into late-stage pivotal trials. FDMT's 4D-150 demonstrated up to 89% reduction in injection burden and maintained visual acuity over two years, with phase 3 topline data expected in 2027. Strong financial position with $458M cash and milestone payments, supporting operations into 2H 2028 and minimizing near-term dilution risk. Upcoming FDMT catalysts include 2-year SPECTRA DME data [2H 2026] and phase 3 4FRONT topline results [1H and 2H 2027], with global regulatory alignment. Read the full article on Seeking Alpha
Analysartikel • May 11

Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report

Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
Seeking Alpha • Feb 18

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME. Despite market skepticism about gene therapy, 4DMT's solid science, regulatory clarity, and financial stability make it a compelling investment opportunity. Read the full article on Seeking Alpha
Analysartikel • Nov 24

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 04

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Summary 4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved. Market sell-off appears overdone; 4D's well-funded position and diverse pipeline offer a compelling contrarian bet for risk-tolerant investors. Read the full article on Seeking Alpha
Analysartikel • Aug 10

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 19

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Summary A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024. The global diabetic macular edema market is expected to reach $3.93 billion by 2029. 1E15 vg dose of 4D-710 cleared for dose expansion portion of phase 2 AEROW study; Updated interim data expected in mid-2025. Read the full article on Seeking Alpha
Seeking Alpha • Apr 29

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progress for wet AMD and cystic fibrosis treatments. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases, setting it apart from competitors. FDMT's recent public offering bolsters its position and extends its cash runway to 5.8 years, allowing time for research and clinical trials. I believe FDMT stock is a strong buy, driven by its innovative platform and a robust pipeline with a solid cash position. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. FDMT plans to initiate a Phase 3 trial in wet AMD in Q1 2025, positioning 4D-150 as a promising candidate in the treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. The global cystic fibrosis market is expected to reach $37.04 billion by 2030. The proprietary Therapeutic Vector Evolution platform has the ability to enhance transgene expression and allow for the ability to overcome limitations observed in prior AAV gene therapies. Read the full article on Seeking Alpha

Analys av ersättningar till VD

Hur har David Kirn:s ersättning förändrats jämfört med 4D Molecular Therapeutics:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2026n/an/a

-US$179m

Mar 31 2026n/an/a

-US$161m

Dec 31 2025US$2mUS$667k

-US$140m

Sep 30 2025n/an/a

-US$209m

Jun 30 2025n/an/a

-US$196m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$1mUS$663k

-US$161m

Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Ersättning vs marknad: David s total kompensation ($USD 2.05M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 3.52M ).

Ersättning vs inkomst: Ersättningen för David har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

David Kirn (64 yo)

13yrs
Anställning
US$2,051,343
Kompensation

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc. He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013 and serve...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
John Milligan
Executive Chairman6.1yrsUS$255.00k0.18%
$ 1.3m
David Kirn
Co-Founder13yrsUS$2.05m2.58%
$ 18.8m
Kristian Humer
CFO and Principal Financial & Accounting Officerless than a yearUS$3.99minga uppgifter
Fariborz Kamal
Chief Technical Advisorless than a yearUS$1.44m0.011%
$ 78.3k
Theresa Janke
Co-Founder & Chief of Staff13.7yrsUS$2.70minga uppgifter
Julian Pei
Head of Investor Relations & Corporate Financeno datainga uppgifteringa uppgifter
Katy Barglow
Chief Technical Officerless than a yearinga uppgifteringa uppgifter
Scott Bizily
Chief Legal Officer & Corporate Secretary5yrsinga uppgifter0.016%
$ 113.5k
An Song
Chief Translational Medicine Advisor1.7yrsinga uppgifteringa uppgifter
Noriyuki Kasahara
Chief Scientific Advisorno dataUS$488.91kinga uppgifter
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno datainga uppgifteringa uppgifter
Christopher Simms
Chief Commercial & Business Officer2yrsinga uppgifteringa uppgifter
2.0yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder

Erfaren ledning: FDMT s ledningsgrupp anses vara erfaren ( 2 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
John Milligan
Executive Chairman6.1yrsUS$255.00k0.18%
$ 1.3m
David Kirn
Co-Founder13yrsUS$2.05m2.58%
$ 18.8m
Charles Theuer
Independent Director10.8yrsUS$135.00k0.075%
$ 548.9k
Susannah Gray
Independent Director6.2yrsUS$135.00k0%
$ 0
Paul Utz
Member of Scientific Advisory Board2.8yrsinga uppgifteringa uppgifter
Richard Moss
Member of Scientific Advisory Board2.8yrsinga uppgifteringa uppgifter
Jacob Chacko
Independent Director7.5yrsUS$135.00k0%
$ 0
Shawn Tomasello
Independent Director5.8yrsUS$132.50k0%
$ 0
Amit Gaggar
Member of Scientific Advisory Board2.8yrsinga uppgifteringa uppgifter
Nancy Miller-Rich
Independent Director5.8yrsUS$122.50k0%
$ 0
Arshad Khanani
Chair of Retina Advisory Board2.1yrsinga uppgifteringa uppgifter
Amy Rosenberg
Member of Scientific Advisory Board2.8yrsinga uppgifteringa uppgifter
5.8yrs
Genomsnittlig anställningstid
64.5yo
Genomsnittlig ålder

Erfaren styrelse: FDMT s styrelse anses vara erfaren ( 5.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/09/14 18:27
Aktiekurs vid dagens slut2026/09/11 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

4D Molecular Therapeutics, Inc. bevakas av 20 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Huidong WangBarclays
Eliana MerleBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research